Parent and group
- Ceres Invest100%
VESALE PHARMACEUTICA
ActiveSummary
VESALE PHARMACEUTICA has been active since 1994 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3.1m and a net result of -€362,888. Equity has been growing by about 5% per year since 2018. Its solvency ranks better than 83% of 6,167 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
Source: KBO- Status
- Active since 16-03-1994 Normal situation
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460and 1 other
- Joint committee
- 207 Paritair Comité voor de bedienden uit de scheikundige nijverheid · annual accounts 2025
- Establishment units
- 2.066.742.772 5310 Eghezée, since 12-10-1999
- 2.361.348.994 5032 Gembloux, since 18-07-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 11-12-2025
Board and ownership
Board
- AquitaniaDirector · since 14-05-2025 · permanent representative Anja Imschoot
- MD CONSULTDirector · since 14-05-2025 · permanent representative Mario Debel
- Auditor
- BV PwC Bedrijfsrevisoren
Shareholders
- Ceres Pharma100%· score 532025 annual accounts of Ceres Pharma
- Holdings
- Shares in 1 company Vesale Pharma International
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
Annual accounts 2025
- Gross margin
- €2.2m
- ▲ 109%
- Turnover
- ≈ €9.5m
- estimated
- Loss
- €362,888
- Equity
- €3.1m
- ▼ 10.5%
- Total assets
- €4.0m
- ▼ 11.0%
- Employees on 31-12-2025
- 3
- ▼ 25.0%
Filed on 29-07-2026, 2 days before the deadline
Score breakdownraises riskLoss of €362,888 (financial year 2025)1 change of registered office in 24 monthslowers riskSize: 2.8 FTE, total assets €4.0mLiquidity: current ratio 3.52, cash €1.5mShow the evidence
Checked score
Score 2025
90
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 62% of micro companies in wholesale trade (NACE 46)
Financial strength · tick: 2024
Strong
Solvency
100=
equity 77.1% of total assets
Liquidity
89+42
short-term debt 22.9% · cash 37.4%
Profitability
57-18
return on assets -9.0%
Bankruptcy probability within 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.8%
01-2025: 0.8%● unchanged vs 12-2024
02-2025: 0.8%● unchanged vs 01-2025
03-2025: 0.8%● unchanged vs 02-2025
04-2025: 0.8%● unchanged vs 03-2025
05-2025: 0.8%● unchanged vs 04-2025
06-2025: 0.8%● unchanged vs 05-2025
07-2025: 0.9%▲ +0.1 percentage points vs 06-2025
08-2025: 1.3%▲ +0.4 percentage points vs 07-2025highest value
09-2025: 0.1%▼ -1.2 percentage points vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025lowest value
02-2026: 0.4%▲ +0.3 percentage points vs 01-2026
03-2026: 0.4%● unchanged vs 02-2026
04-2026: 0.4%● unchanged vs 03-2026
05-2026: 0.5%▲ +0.1 percentage points vs 04-2026
06-2026: 0.6%▲ +0.1 percentage points vs 05-2026
07-2026: 0.6%● unchanged vs 06-2026
08-2026: 0.2%▼ -0.4 percentage points vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.2%● unchanged vs 09-2026
11-2026: 0.2%● unchanged vs 10-2026
Credit of up to €270,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 3.52 (3.98 in 2024), above the usual 1.5. Short-term debt is 22.9% and cash 37.4% of total assets. 22.9% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro). It does better than 90% of them on solvency, 88% on liquidity, 43% on profitability and 26% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
2 days early
2024
14 days late
2023
372 days late
2022
29 days late
2021
29 days late
2020
31 days late
2019
16 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 65 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 August (4 of the last 5 accounts filed within 31 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
Recent changes
- · Gazette deed Appointment: PwC Bedrijfsrevisoren BV (statutory auditor)Permanent representative: Wouter Coppens
- · Gazette deed Registered office moved from Noville sur Mehaigne to Isnes
- · Gazette deed Resignations: Vesale Pharma International, Rode Ventures BV and Nathalie GéruzetPermanent representatives: Jehan Lienart van Lidth de Jeude, Pierre Iweins d'Eeckhoutte and 2 others · Appointments: MD Consult BV, Aquitania BV and Jehan Lienart van Lidth de Jeude
Companies linked to VESALE PHARMACEUTICA
Comparable companies
These companies have the same main activity as VESALE PHARMACEUTICA: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €2.2m and €6.1m, founded between 1990 and 2001.
| Company | Total assets | Gross margin |
|---|---|---|
| VESALE PHARMACEUTICA Gembloux | €4.0m | €2.2m |
| GELIS Wielsbeke | €4.0m | €1.3m |
| MULTI-G Antwerpen | €4.4m | €1.1m |
| SYNAPHARM INDUSTRIAL SYNTHESIS Grâce-Hollogne | €6.1m | €2.7m |
| EURAMEDICS HOSPITAL PRODUCT SERVICES Diepenbeek | €4.9m | €1.8m |
| QP en S Kampenhout | €2.2m | €1.7m |
| MVS IN MOTION Roeselare | €3.9m | €1.5m |
Key facts about VESALE PHARMACEUTICA
- What is the company number of VESALE PHARMACEUTICA?
- The company number of VESALE PHARMACEUTICA is 0452.282.591. The VAT number is the same number with BE in front: BE 0452.282.591.
- Where is VESALE PHARMACEUTICA based?
- The registered office is at Rue Jean Sonet,Isnes 29, 5032 Gembloux.Company details
- What does VESALE PHARMACEUTICA do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of VESALE PHARMACEUTICA?
- The legal form of VESALE PHARMACEUTICA is Public limited company (NV).
- When was VESALE PHARMACEUTICA founded?
- VESALE PHARMACEUTICA was founded on 16-03-1994.
- Is VESALE PHARMACEUTICA still active?
- Yes, VESALE PHARMACEUTICA is an active enterprise in the KBO register.
- How many employees does VESALE PHARMACEUTICA have?
- VESALE PHARMACEUTICA had an average of 2.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does VESALE PHARMACEUTICA fall under?
- In its 2025 annual accounts, VESALE PHARMACEUTICA states joint committee 207 (Paritair Comité voor de bedienden uit de scheikundige nijverheid).
- What is the turnover of VESALE PHARMACEUTICA?
- The turnover in financial year 2025 is ≈ €9.5m. This figure is estimated from the gross margin of €2.2m and 100 comparable companies (NACE 46). It probably lies between €5.6m and €16.0m. In financial year 2021 turnover was €5.9m.
- Is VESALE PHARMACEUTICA profitable?
- In financial year 2025, VESALE PHARMACEUTICA made a loss of €362,888.
- Where can I find the annual accounts of VESALE PHARMACEUTICA?
- VESALE PHARMACEUTICA filed 30 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of VESALE PHARMACEUTICA due?
- VESALE PHARMACEUTICA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies See the other companies in the same group.Ceres Invest · 12 companies
See how customers, suppliers and banks see your own company and what to improve first.